Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

Leslie Iltgen is the new Vice President Investor Relations

  • 05/09/2016
  • Press Release
  • Investor News

Bad Vilbel, September 5, 2016 –


On September 1, 2016 Leslie Iltgen succeeded Dr.
Markus Metzger as Vice President Investor Relations of STADA Arzneimittel AG and is
responsible for the communication with analysts as well as private and institutional
investors. Ms. Iltgen reports to Helmut Kraft, Chief Financial Officer.

Helmut Kraft, Chief Financial Officer of STADA Arzneimittel AG, said: “We thank Dr.
Metzger for his service and successful work over the years. We are delighted to have
secured an experienced and competent Investor Relations Manager for this important
position in our company in Ms. Iltgen and we wish her every success in her new
responsibility.”

Leslie Iltgen has long-standing experience in capital markets. She worked as an equity
analyst in the health care sector for several years and she also has many years of
experience in investor relations. Ms. Iltgen was Deputy Head of Investor Relations at
Fresenius.

In future, Dr. Metzger will take on other challenges in the STADA Group.

Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]